What is the recommended hormone therapy regimen for a 50-year-old perimenopausal woman with an intact uterus?

Recommended Hormone Therapy for a 50-Year-Old Perimenopausal Woman with Intact Uterus

For a 50-year-old perimenopausal woman with an intact uterus, use transdermal 17β-estradiol (50-100 μg patches changed twice weekly) combined with micronized progesterone (200 mg orally for 12-14 days per month) as first-line therapy.

Estrogen Component

The transdermal route is strongly preferred over oral administration for several critical reasons:

• Avoids first-pass hepatic metabolism, which reduces procoagulant effects, inflammatory markers (C-reactive protein), and increases in sex hormone-binding globulin 1
• Lower thromboembolism risk compared to oral formulations—a crucial consideration as VTE risk increases with age 2, 1
• Better metabolic profile for women with hypertension, hypertriglyceridemia, obesity, or diabetes 1

Specific dosing: Start with patches releasing 50 μg of 17β-estradiol daily, changed twice weekly. Adjust to 100 μg if symptoms persist 3, 1. This provides physiological estrogen levels comparable to premenopausal women 4.

Progestogen Component (Essential for Endometrial Protection)

Since she has an intact uterus, progestogen is mandatory to prevent endometrial hyperplasia and cancer 3, 2.

First choice: Micronized progesterone (MP) 200 mg orally for 12-14 days every 28 days 5. This is preferred because recent studies show MP has:

• Lower cardiovascular disease risk
• Lower venous thromboembolism risk
• Adequate endometrial protection 5

Alternative progestogens if MP is unavailable or not tolerated:

• Medroxyprogesterone acetate (MPA) 10 mg for 12-14 days per month
• Dydrogesterone 10 mg for 12-14 days per month 5

Regimen Options Based on Patient Preference

If Monthly Bleeding is Acceptable (Sequential Regimen):

• Transdermal 17β-estradiol 50 μg continuously
• Add oral micronized progesterone 200 mg for 12-14 days each month
• This induces predictable withdrawal bleeding 5

If Avoiding Bleeding is Preferred (Continuous Combined):

• Combined patches with 17β-estradiol + levonorgestrel (e.g., 50 μg estradiol + 7 μg levonorgestrel) applied continuously 5
• Alternative: Oral tablets with 1-2 mg 17β-estradiol + 5 mg dydrogesterone daily 5
• Note: Breakthrough bleeding may occur initially but typically resolves

Important Clinical Considerations

Contraception needs: At age 50 and perimenopausal, spontaneous ovulation remains possible. If contraception is required, consider 17β-estradiol-based combined oral contraceptives (e.g., estradiol + nomegestrol acetate or estradiol + dienogest) as first choice 5, 4. These provide both hormone replacement and reliable contraception.

Duration of therapy: Continue until the average age of natural menopause (45-55 years), then reassess. For this 50-year-old patient, plan for approximately 5 years of treatment, then individualize based on symptom control and risk-benefit profile 5.

Monitoring: Adjust estradiol dose based on symptom relief and tolerability. The goal is the lowest effective dose 3, 1.

Common Pitfalls to Avoid

• Do not use unopposed estrogen in women with intact uterus—this dramatically increases endometrial cancer risk 2
• Avoid progestogens with anti-androgenic effects if sexual dysfunction or low libido is present, as these can worsen symptoms 5
• Do not prescribe oral estrogen as first-line when transdermal is available—the thrombotic risk difference matters at this age 2, 1
• Ensure adequate progestogen duration: Less than 10 days per month provides insufficient endometrial protection 3, 2

Evidence Context

While the provided guidelines [5-5] focus on premature ovarian insufficiency in younger women, the principles of transdermal estradiol superiority and micronized progesterone preference apply equally to perimenopausal women. The AACE guidelines 3, 2, 3 and Endocrine Society recommendations 1 specifically address this age group and support transdermal delivery with adequate progestogen protection. Recent Cochrane data 6 confirms that combined hormone therapy increases breast cancer and thromboembolism risk, reinforcing the importance of using the safest formulations (transdermal estradiol with micronized progesterone).